UnitedHealth (UNH) Received its Third Buy in a Row

By Ryan Adsit

After Oppenheimer and Credit Suisse gave UnitedHealth (NYSE: UNH) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst John Ransom maintained a Buy rating on UnitedHealth yesterday and set a price target of $310. The company’s shares closed yesterday at $267.30, close to its 52-week high of $272.81.

According to TipRanks.com, Ransom is a 5-star analyst with an average return of 12.8% and a 65.5% success rate. Ransom covers the Services sector, focusing on stocks such as Addus Homecare Corp, LifePoint Health, and Tenet Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $305.13 average price target, representing a 14.2% upside. In a report issued on October 16, Oppenheimer also maintained a Buy rating on the stock with a $295 price target.


See today’s analyst top recommended stocks >>

Based on UnitedHealth’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $56.56 billion and net profit of $3.19 billion. In comparison, last year the company earned revenue of $50.32 billion and had a net profit of $2.49 billion.

Based on the recent corporate insider activity of 185 insiders, corporate insider sentiment is negative on the stock. Last month, Richard Burke, a Director at UNH bought 5,000 shares for a total of $125,400.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.